Design Therapeutics (DSGN) News Today $3.90 -0.11 (-2.74%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.90 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)Two Sigma Investments LP lowered its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 33.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 203,931 shares of the company's stock after selling 100,313 shares during the period. TwoJune 5, 2025 | marketbeat.comDesign Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2June 4, 2025 | globenewswire.comTwo Sigma Advisers LP Decreases Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Two Sigma Advisers LP lessened its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 23.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 233,900 shares of the company's stock after sellJune 1, 2025 | marketbeat.comDesign Therapeutics to Participate in 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comPoint72 Asset Management L.P. Buys 256,010 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)Point72 Asset Management L.P. boosted its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,856,750 shares of the company's stock after buying an additional 256,010 sharesMay 21, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Cuts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)Jacobs Levy Equity Management Inc. lowered its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 93.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,261 shares of the compaMay 21, 2025 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LPDimensional Fund Advisors LP boosted its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 60.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 215,265 shares of the company's stock after acMay 18, 2025 | marketbeat.comMPM Bioimpact LLC Purchases New Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)MPM Bioimpact LLC acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 559,547 shares of the company's stock, valued at approximately $3,452,000. MMay 16, 2025 | marketbeat.comBridgeway Capital Management LLC Has $792,000 Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)Bridgeway Capital Management LLC cut its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 45.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,400 shares of the company'sMay 14, 2025 | marketbeat.comDesign Therapeutics to Participate in 2025 RBC Capital Markets Healthcare ConferenceMay 13, 2025 | globenewswire.comQ2 EPS Forecast for Design Therapeutics Reduced by AnalystDesign Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Analysts at Leerink Partnrs decreased their Q2 2025 earnings per share estimates for Design Therapeutics in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($0.33) peMay 13, 2025 | marketbeat.com776,082 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Bought by Driehaus Capital Management LLCDriehaus Capital Management LLC acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 776,082 shares of the company's stock, valuedMay 12, 2025 | marketbeat.comDesign Therapeutics (DSGN) to Release Quarterly Earnings on WednesdayDesign Therapeutics (NASDAQ:DSGN) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-design-therapeutics-inc-stock/)May 9, 2025 | marketbeat.comDesign Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comDesign Therapeutics To Initiate Phase 2 Biomarker Trial Of DT-168 In FECD In 2H 2025May 3, 2025 | nasdaq.comDesign Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal DystrophyMay 1, 2025 | globenewswire.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Shares Purchased by Walleye Capital LLCWalleye Capital LLC boosted its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 101.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 141,127 shares of the company's stock after buying anApril 24, 2025 | marketbeat.comDesign Therapeutics Announces Update on DT-168 Program for Fuchs Endothelial Corneal Dystrophy at Eyecelerator 2025April 22, 2025 | nasdaq.comDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025April 21, 2025 | globenewswire.comDesign Therapeutics appoints Chris Storgard as CMOApril 19, 2025 | markets.businessinsider.comDesign Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical OfficerApril 17, 2025 | globenewswire.comBright Peak Therapeutics Appoints John Schmid to its Board of DirectorsApril 17, 2025 | markets.businessinsider.comWall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?March 12, 2025 | msn.comDesign Therapeutics price target raised to $5 from $4 at RBC CapitalMarch 11, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) Gets a Hold from RBC CapitalMarch 11, 2025 | markets.businessinsider.comDesign Therapeutics (DSGN) to Release Earnings on TuesdayDesign Therapeutics (NASDAQ:DSGN) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comDesign Therapeutics sees cash runway into 2029March 10, 2025 | markets.businessinsider.comDesign Therapeutics provides corporate highlights, anticipated milestonesMarch 10, 2025 | markets.businessinsider.comDesign Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPSDesign Therapeutics (NASDAQ:DSGN - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04.March 10, 2025 | marketbeat.comDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comDesign Therapeutics to Participate in Leerink’s Global Healthcare ConferenceMarch 3, 2025 | markets.businessinsider.comDesign Therapeutics to Participate in Leerink's Global Healthcare ConferenceMarch 3, 2025 | globenewswire.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Short Interest UpdateDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 2,920,000 shares, a growth of 8.1% from the December 31st total of 2,700,000 shares. Based on an average daily trading volume, of 169,900 shares, the days-to-cover ratio is currently 17.2 days. Currently, 9.3% of the shares of the stock are short sold.February 4, 2025 | marketbeat.comDesign Therapeutics: Not A Complete Washout Despite SetbackJanuary 31, 2025 | seekingalpha.comAssenagon Asset Management S.A. Trims Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)Assenagon Asset Management S.A. decreased its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 83.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 56,617 shares of the company's stock after selling 289,575 sJanuary 26, 2025 | marketbeat.comDesign Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Up 8.1% in DecemberDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,920,000 shares, a growth of 8.1% from the December 15th total of 2,700,000 shares. Currently, 9.3% of the shares of the company are short sold. Based on an average daily volume of 169,900 shares, the days-to-cover ratio is presently 17.2 days.January 19, 2025 | marketbeat.comDesign Therapeutics Updates Corporate Presentation for InvestorsJanuary 13, 2025 | tipranks.comDeepa Prasad Sells 3,806 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) StockDecember 20, 2024 | insidertrades.comDesign Therapeutics (NASDAQ:DSGN) Stock Quotes, Forecast and News SummaryDecember 20, 2024 | benzinga.comInsider Selling: Design Therapeutics, Inc. (NASDAQ:DSGN) Director Sells 3,806 Shares of StockDesign Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) Director Deepa Prasad sold 3,806 shares of Design Therapeutics stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $6.27, for a total value of $23,863.62. Following the sale, the director now directly owns 20,000 shares of the company's stock, valued at $125,400. This trade represents a 15.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.December 19, 2024 | marketbeat.comFmr LLC Has $4.46 Million Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Fmr LLC grew its position in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 922.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 828,665 shares of the company's stock after buying an additional 747,64December 14, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Buys 697,368 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)Frazier Life Sciences Management L.P. raised its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 58.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,892,547 shares of the company's stock afterDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN)Jacobs Levy Equity Management Inc. lessened its holdings in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 41.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 280,271 shares of the company's stock after selling 19December 9, 2024 | marketbeat.comPoint72 Asset Management L.P. Boosts Stake in Design Therapeutics, Inc. (NASDAQ:DSGN)Point72 Asset Management L.P. raised its holdings in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 61.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,600,740 sharesDecember 8, 2024 | marketbeat.comDesign Therapeutics to Participate in Multiple Upcoming Investor ConferencesNovember 13, 2024 | globenewswire.comCautious Optimism for Design Therapeutics Amid Promising Developments and Financial ChallengesNovember 13, 2024 | markets.businessinsider.comRBC Capital Remains a Hold on Design Therapeutics (DSGN)November 9, 2024 | markets.businessinsider.comDesign Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM PortfolioNovember 7, 2024 | globenewswire.comWe're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash WiselyNovember 6, 2024 | finance.yahoo.comDesign Therapeutics (NASDAQ:DSGN) Stock, Short Interest ReportOctober 12, 2024 | benzinga.com Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address DSGN Media Mentions By Week DSGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSGN News Sentiment▼1.680.87▲Average Medical News Sentiment DSGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSGN Articles This Week▼11▲DSGN Articles Average Week Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRAX News ARDX News LENZ News OCS News ZYME News NTLA News NUVB News PHAR News IMNM News AVBP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DSGN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DSGN Stock Free DSGN Stock Alerts